• ru
  • en

+7 (495) 782-23-42

  • Home
  • About us
  • Team
    • Management team
    • Advisory Board
  • Portfolio companies
    • Exited investments
    • Current investments
  • News
  • Contact

RBV Capital is a dedicated life sciences venture capital fund established in 2014 investing into innovative biomedical projects globally 

At RBV Capital, we are building a diversified portfolio of early-stage breakthrough assets.

Our investment strategy focuses on innovative science addressing critical unmet medical needs, and relies on selecting strong management teams with a clear vision.

We are interested in biopharmaceuticals, biomedical technology and services, bioinformatics and healthcare IT, and medical device companies.

News

25
dec

PanDx raises seed investment to develop a versatile catheter to treat severe GI conditions

RBV Capital (backed by Alexey Repik’s R-Pharmand RVC) invested RUB 105 million (ca. $1.5M) in PanDx, a UK-based company developing a novel catheter to treat acute pancreatitis and other severe conditions of the gastrointestinal tract (GI).

More
23
dec

Botkin.AI raises $2M to further develop its medical AI platform

Intellogic LLC, raised 160M rubles (ca $2M) in its Series B investment round to further develop its artificial intelligence platform for the analysis of medical images, Botkin.AI.

More
3
dec

Pipeline Therapeutics Appoints Julie Iwashita as Vice President of Clinical Operations

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations.

More

All rights to the materials of this website are held by the partners of the RusBio Ventures Limited Partnership (Investment Partnership Agreement dated 10 October 2014)